Single-cell transcriptomic analysis reveals CD8 + T cell heterogeneity and identifies a prognostic signature in cervical cancer

BMC Cancer, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 18, 2025

Abstract Background In recent years, immunotherapy has made significant progress. However, the understanding of heterogeneity and function T cells, particularly CD8 + in cervical cancer (CESC) microenvironment remains insufficient. We aim to characterize heterogeneity, developmental trajectory, regulatory network, intercellular communication cells squamous cell carcinoma construct a prognostic risk model based on transcriptomic characteristics cells. Methods integrated single-cell RNA sequencing data from CESC tumor samples with bulk transcriptome TCGA GEO databases. identified subsets microenvironment, revealing interactions between other types through analysis. Pseudotime trajectory analysis revealed dynamic transcriptional regulation during differentiation functional acquisition processes. constructed network for identifying key transcription factors. Based cell-related genes, comprising eight core genes was developed validated using machine learning. Results four distinct subsets, namely progenitor, intermediate, proliferative, terminally differentiated, each exhibiting unique properties. interact macrophages different ligand-receptor networks, including CCL-CCR signaling pathway costimulatory molecules. Sorafenib as potential immunotherapeutic drug screening. Experimental validation demonstrated that sorafenib enhances cytotoxicity by increasing secretion IFN-γ TNF-α, thereby significantly inhibiting invasiveness survival Conclusions Our study provides valuable insights into diversity CESC. demonstrate signature may serve tool stratification patients Additionally, our finding suggests could be promising therapeutic candidate improving antitumor immunity this patient population.

Language: Английский

Herbal drug‑based nanotherapy for hepatocellular carcinoma: Quercetin‑contained nanocarrier as a multipurpose therapeutic agent against hepatocellular carcinoma (Review)

Biomedical Reports, Journal Year: 2024, Volume and Issue: 22(2)

Published: Dec. 9, 2024

Cancer remains one of the leading causes morbidity and mortality worldwide, with hepatocellular carcinoma (HCC) accounting for ~75% all primary liver cancers exhibiting a high incidence rate. Unfortunately, response rate to chemotherapeutic agents cancer is relatively low, primarily due development drug resistance lack targeted therapeutic agents. The present study focused on anticancer mechanisms quercetin innovative nanocarriers designed enhance its efficacy against HCC while mitigating resistance. Quercetin demonstrates diverse array biological activities, making it promising candidate applications. Its include inhibition tumor cell cycle, induction apoptosis, modulation reactive oxygen species Given these properties, extensive research has been conducted in pharmaceutical engineering develop well‑designed that incorporate quercetin. These aim improve bioavailability targeting quercetin, thereby enhancing overcoming challenges associated Through this approach, could potentially play pivotal role future treatment, providing synergistic effect when combined traditional chemotherapy improved patient outcomes.

Language: Английский

A New Cuproptosis-Related lncRNAs Model for Predicting the Prognosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma and Experimental Validation of LINC01269

International Journal of General Medicine, Journal Year: 2024, Volume and Issue: Volume 17, P. 6009 - 6027

Published: Dec. 1, 2024

Hepatocellular carcinoma (HCC) triggered by Hepatitis B virus (HBV) remains a significant clinical challenge, necessitating novel therapeutic interventions. Copper ionophores, recognized for introducing an innovative type of programmed cell death termed cuproptosis, present promising potentials cancer therapy. Nevertheless, The role cuproptosis-related lncRNAs (CRLRs) in HBV-HCC has not been clearly elucidated. This study utilised univariate Cox, least absolute shrinkage and selection operator (LASSO), multivariable Cox regression analyses to establish signature CRLRs HBV-HCC. prognostic model was validated with independent internal validation cohort, combined parameters, used construct nomogram patient survival predictions. Gene Ontology (GO) Set Enrichment Analysis (GSEA) were employed explore associated biological pathways. Additionally, protein-protein interaction (PPI) network developed, implications tumour mutational burden (TMB) drug response examined. A comprehensive bioinformatics analysis these hub performed, followed experimental through quantitative real-time PCR (qRT-PCR) functional cellular assays. showed high predictive accuracy survival. GO GSEA indicated that are involved pathways related oestrogen metabolism. PPI consisting 201 nodes 568 edges the TMB differed significantly between high- low-risk groups. Analyses identified three CRLRs, SOS1-IT1, AC104695.3, LINC01269, which differentially expressed HCC tissues. In vitro, LINC01269 found enhance proliferation, invasion, migration. first systematic exploration roles demonstrates their critical involvement disease's pathogenesis possible implication. distinct expression patterns suggest may facilitate targets.

Language: Английский